PROGNOSTIC FACTORS FOR SURVIVAL OF MEN1 PATIENTS WITH DUODENOPANCREATIC TUMORS METASTATIC TO THE LIVER: RESULTS FROM THE DMSG
Duodenopancreatic neuroendocrine tumors (DP-NETs) develop in a majority of patients with multiple endocrine neoplasia type 1 (MEN1) and are the leading cause of death. Overall survival (OS) and prognostic factors for patients with liver metastases from DP-NETs are not known. This was a cohort study...
Gespeichert in:
| Veröffentlicht in: | Endocrine practice 2017-06, Vol.23 (6), p.641-648 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 648 |
|---|---|
| container_issue | 6 |
| container_start_page | 641 |
| container_title | Endocrine practice |
| container_volume | 23 |
| creator | Conemans, Elfi B Nell, Sjoerd Pieterman, Carolina R C de Herder, Wouter W Dekkers, Olaf M Hermus, Ad R van der Horst-Schrivers, Anouk N Bisschop, Peter H Havekes, Bas Drent, Madeleine L Vriens, Menno R Valk, Gerlof D |
| description | Duodenopancreatic neuroendocrine tumors (DP-NETs) develop in a majority of patients with multiple endocrine neoplasia type 1 (MEN1) and are the leading cause of death. Overall survival (OS) and prognostic factors for patients with liver metastases from DP-NETs are not known.
This was a cohort study using the Dutch National MEN1 database, which includes >90% of the Dutch MEN1 population treated between 1990 and 2014. OS was assessed with time to event analysis, and prognostic factors were evaluated.
A total of 56% of the MEN1 patients (n = 220) were diagnosed with a DP-NET, of who 34 (15%) developed DP-NET liver metastases. Median age at liver metastases diagnosis was 53 years (range 31-74). Of those patients, 16 patients (47%) had died after a median follow-up of 4 years (range 0.3-12.3). OS at 2, 5, and 10 years were 91%, 65%, and 50%, respectively. A trend towards worse survival was seen in males compared to females (5-year OS 58% versus 75%, P = .07) and also in patients with multiple liver metastases compared to patients with solitary liver metastasis (59 versus 83%, P = .09).
Despite the fairly indolent course of DP-NET liver metastases in MEN1 patients, half of the population was deceased after 10 years. Sex and tumor load at diagnosis of liver metastases are possible prognostic factors for worse survival.
DMSG = DutchMEN1 Study Group; D-NET = duodenal neuroendocrine tumor; DP-NET = duodenopancreatic neuroendocrine tumor; HPF = high-power field; Ki67 LI = Ki67 labeling index; MEN1 = multiple endocrine neoplasia type 1; NET = neuroendocrine tumor; OS = overall survival; P-NET = pancreatic neuroendocrine tumor; PPI = proton pump inhibitor; ULN = upper limit of normal; WHO = World Health Organization. |
| doi_str_mv | 10.4158/EP161639.OR |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1870988535</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1870988535</sourcerecordid><originalsourceid>FETCH-LOGICAL-c317t-dbfda7a6ffcceb46678b443cd1f4141e6d2b7eba8a58f40345e0de60899b0f943</originalsourceid><addsrcrecordid>eNpdkc1P4zAQxS20iK_dE3dkaS8robCe2ElsblHqtJGSuHKcwi3KhyOBWgoJPeyB_52UAoc9zejp955m9BC6BHLDwON_5RJ88Km4UfoInYGgzHEZoT-m3aPE4QLuT9H5OD4S4hIB_ASdutx1PQpwht6WWs1zVZgkwnEYGaULHCuNi1KvklWYYhXjTOaAl6FJZG4KfJeYBZ6VaiZztQzzSMtwbzZltvdm0oSFOSgKm4XEabKS-hZrWZTpZI-1yj70WVbMf6Ljvl6P9tfnvEBlLE20cFI1T6IwdVoKwavTNX1XB7Xf921rG-b7AW8Yo20HPQMG1u_cJrBNzWuP99PrzLOksz7hQjSkF4xeoD-H3Odh-7Kz42u1eRhbu17XT3a7GyvgARGce9Sb0N__oY_b3fA0XVeBcEngBlPqRF0fqHbYjuNg--p5eNjUw78KSLVvpfpqpVJ6oq8-M3fNxnbf7FcN9B0Qnn09</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1920727899</pqid></control><display><type>article</type><title>PROGNOSTIC FACTORS FOR SURVIVAL OF MEN1 PATIENTS WITH DUODENOPANCREATIC TUMORS METASTATIC TO THE LIVER: RESULTS FROM THE DMSG</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Conemans, Elfi B ; Nell, Sjoerd ; Pieterman, Carolina R C ; de Herder, Wouter W ; Dekkers, Olaf M ; Hermus, Ad R ; van der Horst-Schrivers, Anouk N ; Bisschop, Peter H ; Havekes, Bas ; Drent, Madeleine L ; Vriens, Menno R ; Valk, Gerlof D</creator><creatorcontrib>Conemans, Elfi B ; Nell, Sjoerd ; Pieterman, Carolina R C ; de Herder, Wouter W ; Dekkers, Olaf M ; Hermus, Ad R ; van der Horst-Schrivers, Anouk N ; Bisschop, Peter H ; Havekes, Bas ; Drent, Madeleine L ; Vriens, Menno R ; Valk, Gerlof D</creatorcontrib><description>Duodenopancreatic neuroendocrine tumors (DP-NETs) develop in a majority of patients with multiple endocrine neoplasia type 1 (MEN1) and are the leading cause of death. Overall survival (OS) and prognostic factors for patients with liver metastases from DP-NETs are not known.
This was a cohort study using the Dutch National MEN1 database, which includes >90% of the Dutch MEN1 population treated between 1990 and 2014. OS was assessed with time to event analysis, and prognostic factors were evaluated.
A total of 56% of the MEN1 patients (n = 220) were diagnosed with a DP-NET, of who 34 (15%) developed DP-NET liver metastases. Median age at liver metastases diagnosis was 53 years (range 31-74). Of those patients, 16 patients (47%) had died after a median follow-up of 4 years (range 0.3-12.3). OS at 2, 5, and 10 years were 91%, 65%, and 50%, respectively. A trend towards worse survival was seen in males compared to females (5-year OS 58% versus 75%, P = .07) and also in patients with multiple liver metastases compared to patients with solitary liver metastasis (59 versus 83%, P = .09).
Despite the fairly indolent course of DP-NET liver metastases in MEN1 patients, half of the population was deceased after 10 years. Sex and tumor load at diagnosis of liver metastases are possible prognostic factors for worse survival.
DMSG = DutchMEN1 Study Group; D-NET = duodenal neuroendocrine tumor; DP-NET = duodenopancreatic neuroendocrine tumor; HPF = high-power field; Ki67 LI = Ki67 labeling index; MEN1 = multiple endocrine neoplasia type 1; NET = neuroendocrine tumor; OS = overall survival; P-NET = pancreatic neuroendocrine tumor; PPI = proton pump inhibitor; ULN = upper limit of normal; WHO = World Health Organization.</description><identifier>ISSN: 1530-891X</identifier><identifier>EISSN: 1934-2403</identifier><identifier>DOI: 10.4158/EP161639.OR</identifier><identifier>PMID: 28225311</identifier><language>eng</language><publisher>United States: Elsevier Limited</publisher><subject>Adult ; Aged ; Amputation ; Breast cancer ; Cause of Death ; Clinical medicine ; Databases, Factual ; Duodenal Neoplasms - mortality ; Duodenal Neoplasms - pathology ; Epidemiology ; Female ; Humans ; Liver ; Liver Neoplasms - mortality ; Liver Neoplasms - secondary ; Male ; Medical imaging ; Medical prognosis ; Metastasis ; Middle Aged ; Multiple Endocrine Neoplasia Type 1 - mortality ; Netherlands ; Neuroendocrine tumors ; Neuroendocrine Tumors - mortality ; Neuroendocrine Tumors - secondary ; Pancreatic cancer ; Pancreatic Neoplasms - mortality ; Pancreatic Neoplasms - pathology ; Patients ; Prognosis ; Survival Rate ; Tumors</subject><ispartof>Endocrine practice, 2017-06, Vol.23 (6), p.641-648</ispartof><rights>Copyright Allen Press Publishing Services Jun 2017</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c317t-dbfda7a6ffcceb46678b443cd1f4141e6d2b7eba8a58f40345e0de60899b0f943</citedby><cites>FETCH-LOGICAL-c317t-dbfda7a6ffcceb46678b443cd1f4141e6d2b7eba8a58f40345e0de60899b0f943</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28225311$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Conemans, Elfi B</creatorcontrib><creatorcontrib>Nell, Sjoerd</creatorcontrib><creatorcontrib>Pieterman, Carolina R C</creatorcontrib><creatorcontrib>de Herder, Wouter W</creatorcontrib><creatorcontrib>Dekkers, Olaf M</creatorcontrib><creatorcontrib>Hermus, Ad R</creatorcontrib><creatorcontrib>van der Horst-Schrivers, Anouk N</creatorcontrib><creatorcontrib>Bisschop, Peter H</creatorcontrib><creatorcontrib>Havekes, Bas</creatorcontrib><creatorcontrib>Drent, Madeleine L</creatorcontrib><creatorcontrib>Vriens, Menno R</creatorcontrib><creatorcontrib>Valk, Gerlof D</creatorcontrib><title>PROGNOSTIC FACTORS FOR SURVIVAL OF MEN1 PATIENTS WITH DUODENOPANCREATIC TUMORS METASTATIC TO THE LIVER: RESULTS FROM THE DMSG</title><title>Endocrine practice</title><addtitle>Endocr Pract</addtitle><description>Duodenopancreatic neuroendocrine tumors (DP-NETs) develop in a majority of patients with multiple endocrine neoplasia type 1 (MEN1) and are the leading cause of death. Overall survival (OS) and prognostic factors for patients with liver metastases from DP-NETs are not known.
This was a cohort study using the Dutch National MEN1 database, which includes >90% of the Dutch MEN1 population treated between 1990 and 2014. OS was assessed with time to event analysis, and prognostic factors were evaluated.
A total of 56% of the MEN1 patients (n = 220) were diagnosed with a DP-NET, of who 34 (15%) developed DP-NET liver metastases. Median age at liver metastases diagnosis was 53 years (range 31-74). Of those patients, 16 patients (47%) had died after a median follow-up of 4 years (range 0.3-12.3). OS at 2, 5, and 10 years were 91%, 65%, and 50%, respectively. A trend towards worse survival was seen in males compared to females (5-year OS 58% versus 75%, P = .07) and also in patients with multiple liver metastases compared to patients with solitary liver metastasis (59 versus 83%, P = .09).
Despite the fairly indolent course of DP-NET liver metastases in MEN1 patients, half of the population was deceased after 10 years. Sex and tumor load at diagnosis of liver metastases are possible prognostic factors for worse survival.
DMSG = DutchMEN1 Study Group; D-NET = duodenal neuroendocrine tumor; DP-NET = duodenopancreatic neuroendocrine tumor; HPF = high-power field; Ki67 LI = Ki67 labeling index; MEN1 = multiple endocrine neoplasia type 1; NET = neuroendocrine tumor; OS = overall survival; P-NET = pancreatic neuroendocrine tumor; PPI = proton pump inhibitor; ULN = upper limit of normal; WHO = World Health Organization.</description><subject>Adult</subject><subject>Aged</subject><subject>Amputation</subject><subject>Breast cancer</subject><subject>Cause of Death</subject><subject>Clinical medicine</subject><subject>Databases, Factual</subject><subject>Duodenal Neoplasms - mortality</subject><subject>Duodenal Neoplasms - pathology</subject><subject>Epidemiology</subject><subject>Female</subject><subject>Humans</subject><subject>Liver</subject><subject>Liver Neoplasms - mortality</subject><subject>Liver Neoplasms - secondary</subject><subject>Male</subject><subject>Medical imaging</subject><subject>Medical prognosis</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Multiple Endocrine Neoplasia Type 1 - mortality</subject><subject>Netherlands</subject><subject>Neuroendocrine tumors</subject><subject>Neuroendocrine Tumors - mortality</subject><subject>Neuroendocrine Tumors - secondary</subject><subject>Pancreatic cancer</subject><subject>Pancreatic Neoplasms - mortality</subject><subject>Pancreatic Neoplasms - pathology</subject><subject>Patients</subject><subject>Prognosis</subject><subject>Survival Rate</subject><subject>Tumors</subject><issn>1530-891X</issn><issn>1934-2403</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNpdkc1P4zAQxS20iK_dE3dkaS8robCe2ElsblHqtJGSuHKcwi3KhyOBWgoJPeyB_52UAoc9zejp955m9BC6BHLDwON_5RJ88Km4UfoInYGgzHEZoT-m3aPE4QLuT9H5OD4S4hIB_ASdutx1PQpwht6WWs1zVZgkwnEYGaULHCuNi1KvklWYYhXjTOaAl6FJZG4KfJeYBZ6VaiZztQzzSMtwbzZltvdm0oSFOSgKm4XEabKS-hZrWZTpZI-1yj70WVbMf6Ljvl6P9tfnvEBlLE20cFI1T6IwdVoKwavTNX1XB7Xf921rG-b7AW8Yo20HPQMG1u_cJrBNzWuP99PrzLOksz7hQjSkF4xeoD-H3Odh-7Kz42u1eRhbu17XT3a7GyvgARGce9Sb0N__oY_b3fA0XVeBcEngBlPqRF0fqHbYjuNg--p5eNjUw78KSLVvpfpqpVJ6oq8-M3fNxnbf7FcN9B0Qnn09</recordid><startdate>201706</startdate><enddate>201706</enddate><creator>Conemans, Elfi B</creator><creator>Nell, Sjoerd</creator><creator>Pieterman, Carolina R C</creator><creator>de Herder, Wouter W</creator><creator>Dekkers, Olaf M</creator><creator>Hermus, Ad R</creator><creator>van der Horst-Schrivers, Anouk N</creator><creator>Bisschop, Peter H</creator><creator>Havekes, Bas</creator><creator>Drent, Madeleine L</creator><creator>Vriens, Menno R</creator><creator>Valk, Gerlof D</creator><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>201706</creationdate><title>PROGNOSTIC FACTORS FOR SURVIVAL OF MEN1 PATIENTS WITH DUODENOPANCREATIC TUMORS METASTATIC TO THE LIVER: RESULTS FROM THE DMSG</title><author>Conemans, Elfi B ; Nell, Sjoerd ; Pieterman, Carolina R C ; de Herder, Wouter W ; Dekkers, Olaf M ; Hermus, Ad R ; van der Horst-Schrivers, Anouk N ; Bisschop, Peter H ; Havekes, Bas ; Drent, Madeleine L ; Vriens, Menno R ; Valk, Gerlof D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c317t-dbfda7a6ffcceb46678b443cd1f4141e6d2b7eba8a58f40345e0de60899b0f943</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Amputation</topic><topic>Breast cancer</topic><topic>Cause of Death</topic><topic>Clinical medicine</topic><topic>Databases, Factual</topic><topic>Duodenal Neoplasms - mortality</topic><topic>Duodenal Neoplasms - pathology</topic><topic>Epidemiology</topic><topic>Female</topic><topic>Humans</topic><topic>Liver</topic><topic>Liver Neoplasms - mortality</topic><topic>Liver Neoplasms - secondary</topic><topic>Male</topic><topic>Medical imaging</topic><topic>Medical prognosis</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Multiple Endocrine Neoplasia Type 1 - mortality</topic><topic>Netherlands</topic><topic>Neuroendocrine tumors</topic><topic>Neuroendocrine Tumors - mortality</topic><topic>Neuroendocrine Tumors - secondary</topic><topic>Pancreatic cancer</topic><topic>Pancreatic Neoplasms - mortality</topic><topic>Pancreatic Neoplasms - pathology</topic><topic>Patients</topic><topic>Prognosis</topic><topic>Survival Rate</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Conemans, Elfi B</creatorcontrib><creatorcontrib>Nell, Sjoerd</creatorcontrib><creatorcontrib>Pieterman, Carolina R C</creatorcontrib><creatorcontrib>de Herder, Wouter W</creatorcontrib><creatorcontrib>Dekkers, Olaf M</creatorcontrib><creatorcontrib>Hermus, Ad R</creatorcontrib><creatorcontrib>van der Horst-Schrivers, Anouk N</creatorcontrib><creatorcontrib>Bisschop, Peter H</creatorcontrib><creatorcontrib>Havekes, Bas</creatorcontrib><creatorcontrib>Drent, Madeleine L</creatorcontrib><creatorcontrib>Vriens, Menno R</creatorcontrib><creatorcontrib>Valk, Gerlof D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Endocrine practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Conemans, Elfi B</au><au>Nell, Sjoerd</au><au>Pieterman, Carolina R C</au><au>de Herder, Wouter W</au><au>Dekkers, Olaf M</au><au>Hermus, Ad R</au><au>van der Horst-Schrivers, Anouk N</au><au>Bisschop, Peter H</au><au>Havekes, Bas</au><au>Drent, Madeleine L</au><au>Vriens, Menno R</au><au>Valk, Gerlof D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>PROGNOSTIC FACTORS FOR SURVIVAL OF MEN1 PATIENTS WITH DUODENOPANCREATIC TUMORS METASTATIC TO THE LIVER: RESULTS FROM THE DMSG</atitle><jtitle>Endocrine practice</jtitle><addtitle>Endocr Pract</addtitle><date>2017-06</date><risdate>2017</risdate><volume>23</volume><issue>6</issue><spage>641</spage><epage>648</epage><pages>641-648</pages><issn>1530-891X</issn><eissn>1934-2403</eissn><abstract>Duodenopancreatic neuroendocrine tumors (DP-NETs) develop in a majority of patients with multiple endocrine neoplasia type 1 (MEN1) and are the leading cause of death. Overall survival (OS) and prognostic factors for patients with liver metastases from DP-NETs are not known.
This was a cohort study using the Dutch National MEN1 database, which includes >90% of the Dutch MEN1 population treated between 1990 and 2014. OS was assessed with time to event analysis, and prognostic factors were evaluated.
A total of 56% of the MEN1 patients (n = 220) were diagnosed with a DP-NET, of who 34 (15%) developed DP-NET liver metastases. Median age at liver metastases diagnosis was 53 years (range 31-74). Of those patients, 16 patients (47%) had died after a median follow-up of 4 years (range 0.3-12.3). OS at 2, 5, and 10 years were 91%, 65%, and 50%, respectively. A trend towards worse survival was seen in males compared to females (5-year OS 58% versus 75%, P = .07) and also in patients with multiple liver metastases compared to patients with solitary liver metastasis (59 versus 83%, P = .09).
Despite the fairly indolent course of DP-NET liver metastases in MEN1 patients, half of the population was deceased after 10 years. Sex and tumor load at diagnosis of liver metastases are possible prognostic factors for worse survival.
DMSG = DutchMEN1 Study Group; D-NET = duodenal neuroendocrine tumor; DP-NET = duodenopancreatic neuroendocrine tumor; HPF = high-power field; Ki67 LI = Ki67 labeling index; MEN1 = multiple endocrine neoplasia type 1; NET = neuroendocrine tumor; OS = overall survival; P-NET = pancreatic neuroendocrine tumor; PPI = proton pump inhibitor; ULN = upper limit of normal; WHO = World Health Organization.</abstract><cop>United States</cop><pub>Elsevier Limited</pub><pmid>28225311</pmid><doi>10.4158/EP161639.OR</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1530-891X |
| ispartof | Endocrine practice, 2017-06, Vol.23 (6), p.641-648 |
| issn | 1530-891X 1934-2403 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1870988535 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Adult Aged Amputation Breast cancer Cause of Death Clinical medicine Databases, Factual Duodenal Neoplasms - mortality Duodenal Neoplasms - pathology Epidemiology Female Humans Liver Liver Neoplasms - mortality Liver Neoplasms - secondary Male Medical imaging Medical prognosis Metastasis Middle Aged Multiple Endocrine Neoplasia Type 1 - mortality Netherlands Neuroendocrine tumors Neuroendocrine Tumors - mortality Neuroendocrine Tumors - secondary Pancreatic cancer Pancreatic Neoplasms - mortality Pancreatic Neoplasms - pathology Patients Prognosis Survival Rate Tumors |
| title | PROGNOSTIC FACTORS FOR SURVIVAL OF MEN1 PATIENTS WITH DUODENOPANCREATIC TUMORS METASTATIC TO THE LIVER: RESULTS FROM THE DMSG |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T11%3A04%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=PROGNOSTIC%20FACTORS%20FOR%20SURVIVAL%20OF%20MEN1%20PATIENTS%20WITH%20DUODENOPANCREATIC%20TUMORS%20METASTATIC%20TO%20THE%20LIVER:%20RESULTS%20FROM%20THE%20DMSG&rft.jtitle=Endocrine%20practice&rft.au=Conemans,%20Elfi%20B&rft.date=2017-06&rft.volume=23&rft.issue=6&rft.spage=641&rft.epage=648&rft.pages=641-648&rft.issn=1530-891X&rft.eissn=1934-2403&rft_id=info:doi/10.4158/EP161639.OR&rft_dat=%3Cproquest_cross%3E1870988535%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1920727899&rft_id=info:pmid/28225311&rfr_iscdi=true |